Connor Haskins didn't want to make the drive to save his own life anymore... In 2022, Haskins started feeling faint and had trouble breathing while playing basketball with his friend. He blacked out. And the next thing he knew, he was in a hospital bed.

Rare Diseases Are Less Deadly Thanks to This Industry By Joe Austin, senior analyst, Chaikin Analytics Connor Haskins didn't want to make the drive to save his own life anymore... In 2022, Haskins started feeling faint and had trouble breathing while playing basketball with his friend. He blacked out. And the next thing he knew, he was in a hospital bed. Doctors diagnosed the then-11-year-old Maine boy with late-onset Pompe disease ("LOPD"). About 1 in 40,000 people suffer from this terminal genetic condition. People with LOPD lack an enzyme called alpha-glucosidase ("GAA")... GAA normally breaks down glycogen inside tiny compartments within cells called lysosomes. But without enough GAA, glycogen builds up. This buildup happens throughout the body. And essentially, it causes muscle weakness and pain. It can also harm the carrier's organs and tissues. Although no cure exists yet, LOPD is treatable. But to get the treatment, Haskins and his family had to drive roughly six hours each way from Maine to Boston. In Boston, Haskins would receive enzyme replacement therapy ("ERT"). These IV infusions gave Haskins the GAA that his body couldn't make. But each ERT session took 13 hours. Fortunately, Haskins' treatment could soon get easier... He got a medical port – basically a small, implantable IV – put into his chest. So next year, he hopes to start doing his ERT sessions at home. Haskins can now do a lot of things that seemed impossible just a couple of years ago. He loves hunting with his family and playing basketball with his friends. Despite his LOPD, the ERT sessions allow Haskins to live a mostly normal life. Stories like this show why rare-disease research matters. But there's a big problem... Recommended Links: AIRING TODAY: New Breakthrough Helps You Track Wall Street's Hidden Bets It's a powerful new breakthrough that gives regular folks the chance to make six figures from a single trade by tracking the hidden bets Wall Street makes every day. And today at 1 p.m. Eastern time, Louis Navellier, Eric Fry, and Luke Lango of our corporate affiliate InvestorPlace will reveal this breakthrough along with the man who created it. Click here to learn more, then tune in at 1 p.m. Eastern time. Ex-Wall Street Insider: A Historic Pattern Is Repeating, and Gold Could Soar Past $27,000 A seismic event that has played out only four times in history is likely unfolding again. And signs point to gold soaring past a shocking $27,000 an ounce... yet most Americans have no clue it is even happening. Today, a CEO of a publicly traded company and former Goldman Sachs vice president is pulling back the curtain on this strange story playing out in the upper echelons of world finance. And even if you've never owned an ounce of gold, this could impact everything from your investments to your mortgage. Get the time-sensitive details here. When a disease only affects 1 in 40,000 people, it's hard to find enough patients to test new treatments. So it's difficult to figure out what works best to fight these disorders. Biotech companies can't take shortcuts or make exceptions in clinical trials, either... The technicians conducting the trials need to have the right qualifications. The testing sites need to have the right equipment. And the patients in the study need to be both diverse and medically qualified. Trials often run at the same time across multiple countries, too. That means navigating multiple regulatory regimes – each with its own requirements for approval. Because of all that, the cost of each trial is high. And failures or delays are expensive as well. A Phase III trial currently costs somewhere between $20 million and more than $100 million. The total costs depend heavily on the type of drug, the locations of the trial, and more. The average daily cost of a trial can be up to $55,000. But industry research shows that if faulty data delays a drug, it could cost an average of $500,000 per day in missed sales. That's where clinical contract research organizations ("CROs") come in... In short, CROs serve as the "bridge" between a breakthrough and regulatory approval. Biotech companies turn to CROs to help solve their problem. The CROs have the networks, the expertise, and the reach to find the patients needed to test new treatments. They connect with patient registries. They work with specialized medical centers. They coordinate trials across dozens of countries and languages. Without CROs, most rare-disease treatments would never make it out of the lab. That's why this type of business should grow significantly in the years ahead... Last year, estimates put the size of the CRO market at about $85 billion. It's expected to grow to about $175 billion by 2032. That's a compound annual growth rate of nearly 10%. And when it comes to investing, it ties into a bigger story with biotech right now... The Power Gauge Still Sees Major Strength for Biotech Stocks Regular readers will recall that last month, I discussed a changing landscape for biotech... In the Power Gauge, we can track this corner of the market with the SPDR S&P Biotech Fund (XBI). As I noted last month, the fund is down sharply from its 2021 highs. However, I also pointed out that it had surged since its lows in early April. The Power Gauge has taken note. And it still sees a lot of strength in this corner of the market right now... Today, XBI earns a "very bullish" rating in the Power Gauge. In fact, out of 21 market subsectors, it's one of just four with that top-notch grade. And out of XBI's 130 individual holdings with ratings, 43 are "bullish" or better. So our system sees plenty of strong stocks to choose from in this industry. Put simply, the Power Gauge still says biotech is a great place to look for opportunities today.  Good investing, Joe Austin Market View Major Indexes and Notable Sectors     # Hld:     Bullish     Neutral     Bearish Dow 30 +0.12% 11 10 9 S&P 500 +0.1% 119 235 149 Nasdaq -0.32% 25 53 22 Small Caps +0.52% 466 1040 405 Bonds -0.21% Consumer Staples +1.47% 1 12 24 — According to the Chaikin Power Bar, Small Cap stocks remain somewhat more Bullish than Large Cap stocks. Major indexes are mixed. *  *  *  * Sector Tracker Sector movement over the last 5 days Energy +1.6% Health Care +1.31% Real Estate +0.9% Financial +0.78% Utilities +0.66% Consumer Staples +0.56% Materials +0.18% Industrials -1.12% Consumer Discretionary -1.7% Communication -2.35% Information Technology -4.16% *  *  *  * Industry Focus Insurance Services 13 30 10 Over the past 6 months, the Insurance subsector (KIE) has underperformed the S&P 500 by -19.42%. However, its Power Bar ratio, which measures future potential, is Strong, with more Bullish than Bearish stocks. It is currently ranked #14 of 21 subsectors and has moved up 6 slots over the past week. Top Stocks MCY Mercury General Corp TRV The Travelers Compan CB Chubb Limited *  *  *  * Top Movers Gainers EXPE +17.55% AKAM +14.71% SOLV +7.91% NWSA +6.54% ALB +6.49% Losers TTWO -8.08% XYZ -7.73% TTD -6.32% DXCM -5.21% MCHP -5.17% *  *  *  * Earnings Report Earnings Surprises KKR KKR & Co. Inc. Q3 $1.41 Beat by $0.11 DUK Duke Energy Corporation Q3 $1.81 Beat by $0.06 CEG Constellation Energy Corporation Q3 $3.04 Missed by $-0.08 BAM Brookfield Asset Management Ltd. Q3 $0.41 Beat by $0.01 DK Delek US Holdings, Inc. Q3 $7.13 Beat by $6.95 *  *  *  * You have received this e-mail as part of your subscription to PowerFeed. If you no longer want to receive e-mails from PowerFeed, click here. You're receiving this e-mail at STEVENMAGALLANES520.NIMS@BLOGGER.COM. For questions about your account or to speak with customer service, call +1 (877) 697-6783 (U.S.), 9 a.m. - 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized financial advice. © 2025 Chaikin Analytics, LLC. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Chaikin Analytics, LLC. 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. www.chaikinanalytics.com. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Chaikin Analytics, LLC, does not recommend or endorse any brokers, dealers, or investment advisors. Chaikin Analytics forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Chaikin Analytics, LLC (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.